Plasminogen modulates formation and release of platelet angiogenic regulators by Tykhomyrov, A.A. et al.
ISSN 2409-4943. Ukr. Biochem. J., 2020, Vol. 92, N 1
31
UDC 577.151.6:576.311.348:576.52
Plasminogen modulates formation and release
of Platelet angiogenic regulators
A. A. TykhomyroV, D. D. ZherNoSekoV, T. V. GrINeNko
Palladin Institute of Biochemistry, National Academy of Sciences of Ukraine, kyiv;
e-mail: artem_tykhomyrov@ukr.net
received: 19 July 2019; accepted: 29 November 2019
Platelets store, produce and release a variety of angiogenesis regulators, which can contribute to both 
normal tissue repair and angiopathy-associated pathologies. Plasminogen has been earlier shown to regulate 
some platelet functions, but if it is able to modulate angiogenic capacities of platelets is still poorly studied. 
Thus, the aim of the present study was to evaluate the effects of different plasminogen forms on the formation 
and secretion of angiogenic protein regulators by platelets. human washed platelets were obtained by gel-
filtration on Sepharose-2B. The levels of P-selectin (CD-62P) exposed on the plasma membrane of untreated 
and activated platelets was monitored by flow cytometry. Secretion of platelet-derived vascular endothelial 
growth factor (VEGF) as well as plasminogen fragmentation and angiostatin formation by intact platelets and 
platelet plasma membranes were analyzed by immunoblotting. It was shown that thrombin or collagen expo-
sure resulted in enhanced P-selectin surface expression by platelets, while Lys-form of plasminogen reduced 
agonist-induced platelet secretion. Lys-plasminogen, but not Glu-form, inhibited agonist-induced VEGF re-
lease from platelets. Activation of platelets significantly accelerated plasminogen cleavage and angiostatin 
formation. Anti-actin antibodies inhibited plasminogen fragmentation during incubation with platelet plasma 
membranes indicating surface-exposed actin participation  in plasminogen conversion to angiostatins. The 
present study uncovers a novel function of plasminogen to limit angiogenic potential of platelets via angiosta-
tin formation and inhibition of VEGF secretion. 
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P latelets are the first cells accumulated at the site of vessel injury and have been primarily recognized to play a pivotal role in haemosta‑
sis and thrombosis. However, it is currently accepted 
that platelets also regulate a number of non-haemo‑
static processes, including modulation of immune re‑
sponse, cell migration and angiogenesis. It becomes 
possible because platelets store and form both stimu‑
lators and inhibitors of angiogenesis, which are con‑
tained mainly in their α-granules and released upon 
activation. Platelet-released factors contribute to a 
wide range of pathophysiological events, such as in‑
flammation, tumor growth, proliferative retinopathy, 
atherosclerosis, and autoimmune diseases [1]. For 
example, vascular endothelial growth factor (VEGF) 
is segregated in the specialized α-granules in large 
quantities and deliberated during platelet secretion in 
response to the action of agonists, such as collagen, 
thrombin, or ADP. Platelet-derived VEGF may play 
a protective role to induce reparative angiogenesis 
as a phase of wound healing or may be involved in 
pathological processes, first of all cancers [2]. 
Although the proangiogenic effects of platelets 
have been well-documented, less is known about 
their inhibitory effects on angiogenesis. In terms 
of ‘angiogenic balance’, angiostatin is considered 
as one of the most important VEGF counteracting 
regulators. Angiostatin comprises a range of proteo‑
lytic fragments of plasminogen/plasmin, containing 
various number of kringle domains, mainly the first 
3 to 5 subunits (K1-3, K1-4, K1-4.5, K1-5). Angiosta‑
tin polypeptides specifically inhibit proliferation and 
migration of endothelial cells, induce apoptosis, sup‑
press vessel tube formation, and capillary sprouting , 
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thus reducing tumor angiogenesis and metastasis 
[3]. Initially, angiostatin has been discove red to be 
produced by cancer cells, pro-inflammatory cells 
macrophages and neutrophils [4]. Platelets have 
been recently shown to produce angiostatins, but the 
dependence of their generation upon the functional 
state of platelets remains controversial [5]. Activa‑
tion of platelets can result in exposition of novel 
sites for plasminogen binding and likely is needed 
for angiostatin generation. Among them, the par‑
ticular attention is paid to the surface-exposed actin, 
a cytoskeletal protein of microfilaments, which has 
been demonstrated on the outer surface of various 
normal and transformed cells [6]. It was shown that 
platelets are able to expose actin on their surface 
in an activation-dependent manner [7, 8]. Moreo‑
ver, we have provided experimental evidence that 
surface-exposed actin is involved in plasminogen 
binding to platelet plasma membrane [9]. However, 
if this binding has functional significance remains 
unexplored. In the previous experiments, we have 
established that partially truncated plasminogen 
molecule (Lys-form) interferes agonist-induced ac‑
tin cytoskele ton rearrangements [10] and inhibits 
α-granule release [11]. Surface-exposed actin plays 
a crucial role not only in plasminogen binding, but 
also in its conversion into angiostatins on the outer 
membrane of different cell lines, such as PC-3 pros‑
tate, HT1080 fibrosarcoma, and MDA-MB231 [12]. 
Nevertheless, the precise mechanism of angiostatin 
formation by platelets and putative role of surface-
exposed actin remain unclear. 
In this study, we investigated if plasminogen 
affects release of VEGF and formation of angiostatin 
by human platelets and whether these effects are de‑
pendent on the functional state of platelets. Also, we 
aimed to elucidate whether surface-expressed actin 
is responsible, at least partially, for angiostatin gen‑
eration by platelets.
materials and methods
Chemicals and antibodies. All chemical used 
were of analytical reagent grade quality and pur‑
chased from Sigma-Aldrich (USA), except for those 
specified in the text. Mouse monoclonal anti-VEGF 
antibody was obtained from Abcam (USA, cat. no. 
ab1316), monoclonal phycoerythrin (PE)-conju‑
gated anti-P-selectin (CD-62P) antibody was pur‑
chased from Acris Antibodies, Inc. (USA, cat. no. 
AM26020RP-N). Anti-plasminogen/angiostatin an‑
tibodies were produced in rabbits and characterized 
as described elsewhere [13]. Goat anti-rabbit IgG 
(Sigma-Aldrich, A0545) and anti-mouse IgG (Ab‑
cam, USA, cat. no. ab6789) secondary HPR-conju-
gated antibodies were used.
Platelets. Washed platelets were obtained from 
human platelet-rich plasma by gel-filtration on Se‑
pharose 2B as described elsewhere [9]. Informed 
consent was obtained from all donors (n = 3) in ac‑
cordance with the Declaration of Helsinki, research 
protocols were approved by the Ethical Committee 
of Palladin Institute of Biochemistry of NASU (3rd 
November, 2014, protocol No. 10).
To assess platelet viability and functional 
activi ty, agonist-induced platelet aggregation was 
monitored by optical aggregometry (aggregometer 
Solar AT-02, Republic of Belarus), as described ear‑
lier [9]. All assays were performed within 60-80 min 
after platelet collection. 
P-selectin exposition (flow cytometry assay). 
Flow cytometry assay was used to measure a sur‑
face expression of α-granule marker, P-selectin, on 
the platelet surface. Platelets (2.5×106 per sample) 
resuspended in HEPES buffer were activated by 
thrombin (1.0 NIH unit/ml) or collagen (1.25 mg/ml) 
for 5 min at 37 °C. To study the effects of plasmi‑
nogen on platelet secretion, cells were preincubated 
with Glu- or Lys-plasminogen (1.2 µM) for 3 min 
with or without following activation by agonists. 
Non-stimulated platelets were treated in the same 
manner, except physiological saline was added as a 
vehicle (resting control). After treatment, 20 µl of 
PE-conjugated anti-P-selectin antibodies were add‑
ed to platelet suspensions and incubated for 30 min 
according to manufacturer recommendations. The 
measurement of the intensity of specific PE fluores‑
cence was monitored in each group of platelets with 
the use of Coulter Epics XL device (Beckman Coul‑
ter, USA) via FL3 channel as described earlier [11].
VEGF secretion. To study effects of plasmi‑
nogen on VEGF release, washed platelets (1.52×108 
per sample) were resuspended in HEPES buffer and 
treated as described before, with the exception of 
thrombin (0.1 and 1.0 NIH units/ml) and collagen 
(0.125 and 1.25 mg/ml) concentrations. After treat‑
ment, platelet pellets and releasates were separated 
by centrifugation (1,500 g for 15 min at 15 °C). 
Sedimented platelets were solubilized on ice with 
the non-reducing SDS-containing electrophoretic 
buffer, freshly supplemented with the protease and 
phosphatase inhibitor cocktail PPC 1010, boiled for 
5 min and stored at -20 °C for further analysis.
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Platelet releasate and lysate samples were sub‑
jected to 12% SDS-PAGE and transferred onto nitro‑
cellulose membranes by electroblot. After blocking 
in 5% non-fat dry milk, blots were probed with the 
primary antibodies against VEGF, 1:1000 diluted in 
5% non-fat milk PBS, containing 0.1% Tween-20 
(PBST) overnight at 4 °C. Then, membranes were 
washed five times with PBST and incubated with ap‑
propriate HRP-conjugated secondary antibodies for 
90 min at 37 °C. After washing in PBST, blots were 
developed with the use of the chemiluminescence 
HPR substrate, signals were visualized and digitized 
by TotalLab TL120 software (USA).
Angiostatin generation. Platelets (2×108) treated 
by Lys-plasminogen alone and platelets preincuba-
ted with Lys-plasminogen and then aggregated with 
thrombin (1.0 NIH units/ml) or collagen (1.25 mg/
ml) as described above were separated from re‑
leasates by centrifugation at 1,800 g for 10 min at 
room temperature. Releasates were collected into 
plastic tubes and mixed with the SDS-containing 
non-reducing electrophoretic buffer. Platelet pellets 
were washed twice by 50 mM tris-HCl saline buffer 
(TBS), pH 7.4, by centrifugation and lysed in the 
electrophoretic buffer. Samples of platelet releasates 
and lysates were separated by 5÷15% SDS-PAGE 
and transferred onto nitrocellulose membranes for 
further Western blot analysis.
In order to verify if membrane-associated gene-
ration of angiostatin depends on activation state, 
washed platelets (1.3×108) were activated by the ad‑
dition of thrombin (1.0 NIH units/ml), then aggre‑
gation was monitored for 5 min. After aggregation, 
platelet pellets were separated from the releasates 
using centrifugation (1,800 g for 10 min). After sedi-
mentation, unstimulated and thrombin-stimulated 
platelets were lyzed with ice-cold hypotonic saline 
(0.2% NaCl) at 4 °C with constant stirring as de‑
scribed previously [14]. Membranes were separated 
by centrifugation at 13,000 for 10 min at 4 °C, and 
isolated membranes were washed twice and resus‑
pended in TBS. Membranes of resting and activated 
platelets were incubated with Glu-plasminogen in 
physiological concentration (1.45 µM) during 3 h at 
37 °C. Then, suspensions were mixed with the elec‑
trophoretic buffer and loaded onto 10% SDS-PAGE 
in the volumes containing 2 µg of plasminogen per 
lane.
In parallel, we established if surface-exposed 
actin may play a role in angiostatin generation by the 
membranes of activated platelets. Prior to the addi‑
tion of plasminogen (for 60 min at 37 °C), anti-actin 
antibodies (8 µg/ml) were added to the membrane 
fraction of thrombin-stimulated platelets and incu‑
bated for 5 min. Other aliquot of platelet membranes 
was incubated with the same amount of non-im‑
mune rabbit IgG and served as a control. For experi‑
ments performed with the serine protease inhibitor 
para-nitrophenyl guanidine benzoate (p-NPGB) 
(5×10‑4 M), platelet membranes were incubated with 
plasminogen for 60 min at 37 °C. After incubation, 
membrane suspensions were mixed with electropho‑
retic buffer and blotted. For detection of proteolytic 
activity impurities that might contribute to plasmi‑
nogen degradation to produce false-positive result, 
rabbit IgG, anti-actin IgG, collagen, and thrombin 
were incubated with Glu-plasminogen and subjected 
to immunochemical analysis. Western blots of plas‑
minogen/angiostatins were performed as described 
above with the use of primary rabbit anti-K1-3 anti‑
bodies followed by incubation with the appropriate 
secondary HRP-conjugated antibodies. Specific im‑
munostaining of plasminogen/angiostatins was de‑
veloped in 0.05% 3,3′-diaminobenzidine solution in 
50 mM Tris-HCl (pH 7.4), with the addition of 0.01% 
hydrogen peroxide.
Statistical analysis. The results were expressed 
as medians for non-normal distributed samples. The 
statistics were performed with the use of Mann-
Whitney U-test. Differences between parameters 
studied in each group were considered to be signifi‑
cant at P less than 0.05.
results and discussion
Lys-plasminogen affects P-selectin exposition. 
P-selectin, or CD-62P, is a platelet α-granule specific 
protein, which mediates platelet-neutrophil adhe‑
sion. During stimulation, P-selectin appears on the 
cell surface and thus serves as a marker of platelet 
activation [15]. P-selectin flow cytometric measure‑
ment data presented as fluorescence intensity curves 
are depicted in Fig. 1. Unlike Glu-plasminogen, Lys-
form of proenzyme slightly increased the level of 
CD-62P on the platelet surface. The fluorescence in‑
tensities of platelets treated with thrombin or colla‑
gen showed a marked increase with stimulation. It is 
worth noting that pretreatment of platelets with Lys-
plasminogen affected thrombin-activated platelet 
secretion in greater extent than collagen-stimulated 
α-granule release.
Effects of plasminogen on VEGF secretion 
by platelets. The ratio of [VEGF releasate]/[VEGF 
A. A. Tykhomyrov, D. D. Zhernosekov, T. V. Grinenko
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Fig. 1. Effects of plasminogen on P-selectin surface expression by resting (A) and agonist-stimulated (B) 























































lysate] was calculated to evaluate effects of plas‑
minogen on growth factor release. As seen in Fig. 
2, Western blot analysis of platelet-derived VEGF 
showed that two forms of plasminogen differently 
affect VEGF secretion. In the samples of resting 
platelets, essentially no VEGF was released dur‑
ing incubation period. Incubation of platelets with 
studied proteins resulted in partial deliberation of 
VEGF from cells to releasates. Only a minor portion 
of VEGF was released during incubation with Glu-
plasminogen, while Lys-form significantly enhanced 
VEGF exocytosis. Growth factor release from plate‑
lets greatly depends on the activator dose and nature, 
with the more potent of the two agonists, thrombin. 
Thrombin 0.1 NIH units/ml induced partial secretion 
of VEGF from platelets, while the greater thrombin 
concentration induced complete VEGF deliberation, 
so that 40 kDa VEGF band appeared to be almost 
undetectable in platelet lysates. Collagen induced 
weaker VEGF release, when used in submaximal 
concentrations (0.125 or 1.25 mg/ml). It is impor‑
tant to note that pretreatment of platelets with Lys-
plasminogen significantly reduced collagen-induced 
VEGF release and, to the greater extent, thrombin-
evoked growth factor secretion. These observations 
are in remarkab le agreement with the data of P-se‑
lectin measurements suggesting that plasminogen 
can modulate exocytosis of platelet α-granules. Dif‑
ferent amounts of VEGF fragments (~20 kDa) were 
detected by western blot in the samples of platelets 
treated with plasminogen alone or followed by ago‑
nist action. Truncated VEGF polypeptides likely re‑
sult from limited proteolysis of the native cytokine 
molecules. 
Platelets mediate Lys-plasminogen-angiostatin 
conversion. In order to determine the extent to which 
platelets promote proteolytical cleavage of Lys-plas‑
minogen directed to the angiostatin appearance and 
to verify if angiostatin generation depends on the 
functional state of platelets, we separated incuba‑
tion medium and cells after treatment procedure. As 
shown in Fig. 3, trace amounts of angiostatin-like 
polypeptides were found in lysates and releasates 
after incubation of platelets with Lys-plasminogen 
alone. However, platelets appeared to be able to 
produce abundance of plasminogen fragments after 
stimulation by two agonists. The major truncated 
products had a mol. weight ~ 45-50 kDa and thus 
might correspond to angiostatins K1-4 and K1-4.5. 
The vast amount of angiostatin-like polypeptides is 
released and accumulated in the incubation medium. 
Activation of platelets with collagen resulted in the 
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Fig. 2. Effects of plasminogen on the VEGF secretion by resting platelets (A) and agonist-stimulated plate-
lets (B): 1 – control (resting platelets), 2 – Glu-Pg, 3 – Lys-Pg, 4 – Thr (0.1 NIH units/ml), 5 – Thr (1.0 NIH 
units/ml), 6 – Lys-Pg + Thr (1.0 NIH units/ml), 7 – Col (0.125 mg/ml), 8 – Col (1.25 mg/ml), 9 – Lys-Pg + Col 

















































generation of minor protein products of lower mol. 
weights (38-25 kDa), which were developed weakly 
in the samples of thrombin-stimulated cells.
Plasminogen fragmentation is a surface-
related process. To test the potential significance 
of cell membranes for plasminogen conversion into 
angiostatins, native proenzyme form was incubated 
separately with whole cells and the cell membrane 
fraction. The reactions were subjected to immunob‑
lotting to probe for the presence of angiostatin-like 
products (Fig. 4, A). 
Like Lys-plasminogen, Glu-form was more 
actively cleaved by activated platelets than resting 
cells. Loss of plasminogen was observed after 3 h of 
incubation with thrombin-activated platelets, and the 
majority of different angiostatin species migrated in 
SDS-PAGE at the mol. weight range of 50-25 kDa. 
During more prolonged incubation of Glu-plasmi‑
nogen with platelets, the degree of plasminogen 
to angiostatin conversion increased over the next 
13 h. Moreover, in the case of activated platelets, 
16 h incubation resulted in complete disappearance 
of plasminogen and further degradation of angio‑
statin-like products. A similar profile of plasmino‑
gen degradation in the presence of cell membranes 
of activated platelets was observed (Fig. 4, B) that 
confirms plasminogen activation by platelets and 
angiostatin-gene rating activity to be rather surface-
related events.
Surface-exposed actin is involved in angio-
statin production by platelets. In order to verify if 
surface-exposed actin makes a contribution, if any, 
to plasminogen to angiostatins conversion, intact or 
anti-actin antibody pretreated membranes of acti‑
vated platelets were incubated with Glu-plasminogen 
for 1 h. As shown in Fig. 5, A, an anti-actin antibody 
did not completely inhibit the generation of angiosta‑
tin by the cell membrane fraction, but significantly 
reduced plasminogen cleavage (Fig. 5, B). This result 
confirms the hypothesis that actin on the outer sur‑
face of the platelet membrane may serve as one of 
the site for angiostatin generation from plasminogen.
To confirm the catalytic role of plasmin in an‑
giostatin generation, we incubated plasminogen with 
the membrane fraction of activated platelets in the 
presence of plasmin inhibitor, p-NPGB. On the basis 
of immunoblot of resultant suspension (Fig. 5, A), 
membranes treated with inhibitor appeared to be 
unable to effectively cleave plasminogen. This in‑
hibitory study indicates that plasmin is the essential 
A. A. Tykhomyrov, D. D. Zhernosekov, T. V. Grinenko
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Fig. 4. Fragmentation of Glu-plasminogen by the whole platelets (A): 1 – Glu-Pg; 2 – intact platelets, 3 h in-
cubation; 3 – Thr-stimulated platelets, 3 h incubation; 4 – intact platelets, 16 h incubation; 5 – Thr-stimulated 
platelets, 16 h incubation) and in the presence of membrane fraction of Thr-stimulated platelets (B): 1 – initial 
point; 2 – 3 h incubation; 3 – 16 h incubation
Fig. 3. Detection of angiostatins in lysates (L) and releasates of resting (control) and stimulated platelets after 








Lys-Pg        L            R            L           R            L            R
Control              Thrombin         Collagen
AS
Lys-Pg






















1             2            3              4           5                              1            2            3
B
37
Fig. 5. Effects of actin blockage on plasminogen fragmentation and angiostatin formation in the presence of 
membranes of thrombin-stimulated platelets: A – immunoblotting of platelet membrane samples incubated 
with Glu-plasminogen without (-) or with (+) pretreatment with anti-actin antibodies; B – profile of angio-
statin generation estimated by the value [AS]/[Pg]; C – control immunoblot on non-specific plasminogen 
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proteinase, which provides angiostatin formation, 
but other proteinases could also be involved in this 
process, but to lesser extent. As seen in Fig. 5, C, any 
of protein reagents used in the study (thrombin, col‑
lagen, anti-actin antibody, non-specific IgG) did not 
contain proteolytic impurities, which might digest 
plasminogen.
Platelets have been reported to participate in 
maintaining angiogenic balance in health and injury 
[16]. Pro- and antiangiogenic mediators are segre‑
gated in different types of platelet α-granules and de‑
liberated differentially to provide precise temporal 
regulation of angiogenesis in a damaged tissue [17]. 
Different platelet-derived proteinases are involved in 
VEGF processing and metabolism. Plasmin, MMPs, 
uPA, elastase and tissue kallikrein have distinct ef‑
fects on VEGF, including cleavage, activation, libe-
ration from extracellular stores, and degradation 
[18]. Based on the present flow cytometry data on 
platelet degranulation (P-selectin detection), we 
expected a release of angiogenesis cytokine from 
platelets on their activation. However, no previous 
study has implicated plasminogen in controlling 
VEGF release by platelets. It has been found that the 
surface of activated platelets may serve as a matrix 
for plasminogen conversion into plasmin mediated 
mainly by internal urokinase-type activator (u-PA) 
exposed on the membranes [19]. Lys-plasminogen is 
converted to plasmin at a faster rate than Glu-form 
on the cell membrane [20]. Plasmin (0.8 CU/ml) has 
been shown to slowly cleave and activate low-affini-
ty protease-activated receptor-4 (PAR-4) facilita-
ting partial release of α-granule content [21]. On the 
other hand, plasmin might reduce thrombin-induced 
signalling through desensitizing high-affinity recep‑
tor (PAR-1) [22]. So, both of these receptors can be 
partially cleaved by plasmin in a dose-dependent 
manner, thus suggesting a regulatory role of this 
proteinase in modulating platelet exocytosis. Likely, 
plasmin may affect GPVI-signalling, which is re‑
sponsible for collagen-evoked platelet exocytosis 
[23]. Plasmin-mediated cleavage of VEGF signifi‑
cantly reduces its overall bioactivity (over 100-fold 
increase in EC50) [18]. Thus, it could be assumed that 
plasminogen/plasmin is responsible for limiting pro-
angiogenic capacities of platelets through reducing 
A. A. Tykhomyrov, D. D. Zhernosekov, T. V. Grinenko
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the sensitivity of platelets to agonist-mediated sig‑
nalling and facilitating VEGF cleavage.
Some authors have found that platelets con‑
stitutively generate angiostatins, internalize, store, 
and release them upon activation [24]. Platelet-
derived angiostatins are thought to counterbalance 
angiogene sis stimulatory effects, including VEGF 
signalling [25]. In our study, we confirmed that in‑
tact platelets are able not only to internalize, but also 
to produce angiostatins de novo, however, the ability 
to cleave plasminogen depends on platelet activa‑
tion state. Platelets stimulated by thrombin or col‑
lagen have enhanced potential (at least, by 10-folds) 
to convert plasminogen to angiostatins compared to 
quiescent cells. It has been earlier shown that MMPs 
are not largely involved in angiostatin generation 
by isolated platelet membranes [14]. Results of our 
inhibitory study with the use of p-NPGB confirm 
that plasmin may play a crucial role in plasminogen 
to angiostatin formation, but minor participation of 
other proteolytical activities cannot be neglected. 
Based on our own observations and above literature 
data, two-step mechanism of angiostatin generation 
by platelets can be proposed. At the first step, pro‑
enzyme molecules interact with platelet surface via 
binding to exposed receptors, and then converted 
into plasmin by means of u-PA (Lys-form converts 
faster than native protein). During the second step, 
active plasmin, being anchored to plasma membrane 
cleaves proenzyme molecules yielding angiostatins. 
Among various candidates on the role of plas‑
minogen/plasmin binding sites on the outer layer 
of platelet membrane, surface-exposed actin may 
be preferable. In the past study [9], we have shown 
that surface-exposed actin is involved in plasmino‑
gen binding to platelets, but the significance of this 
interaction has remained unrevealed yet. In the ex‑
periments with purified proteins, it has been shown 
that plasminogen/plasmin binds actin efficiently 
(kd ~ 140 nMol/l) [12]. Of all plasminogen domains, 
kringle 5 (K5) is supposed to be responsible for 
binding actin. Therefore, cleavage of K5 during 
plasmin auto-proteolysis leads to the formation of 
angiostatin K1-4.5, which is released from the plate‑
let membrane [12, 26]. We showed that production of 
angiostatins in the presence of platelet membranes 
with actin, blocked by specific antibody, is signifi‑
cantly reduced. Therefore, surface-exposed actin 
can participate not only as a plasminogen receptor, 
but also provides a cell-surface-dependent mecha‑
nism for angiostatin genera tion by platelets. To our 
knowled ge, several reports suggest the presence of 
a cell-surface actin form on other cell types. For 
example, surface-exposed β-actin on human cancer 
cell lines, such as PC-3 prostate, HT1080 fibrosar‑
coma, and MDA-MB231 breast cancer, mediates 
plasmin auto-proteolysis even in the absence of free 
sulfhydryl donors [12, 26, 27].
In conclusion, it could be postulated that the 
formation and functioning of the triple complex [ac‑
tivator - plasminogen/plasmin - actin] may represent 
a universal mechanism for the membrane-associated 
angiostatin formation. Collectively, obtained results 
significantly expand our knowledge on the regula‑
tory role of plasminogen in platelet physiology. 
Lys-plasminogen (and native proenzyme, to a lesser 
extent) can be involved in the regulation of angio‑
genesis capacities of platelets via reducing agonist-
induced VEGF release and serving as a substrate 
for angiostatin formation. Since platelets participate 
in the regulation of numerous angiogenesis-related 
physiological and pathological processes, including 
wound healing, cancer growth, cardiovascular 
events, inflammation, and others, the implication of 
plasminogen in such regulation may have a potential 
therapeutic significance.
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Плазміноген модулює 
утворення та вивільнення 
регуляторів ангіогенезу 
тромбоцитами
А. О. Тихомиров, Д. Д. Жерносєков, 
Т. В. Гриненко
Інститут біохімії ім. О. В. Палладіна 
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Тромбоцити зберігають, утворюють та ви‑
вільняють велику кількість регуляторів ангіоге‑
незу, які залучені як до репаративних процесів 
у тканинах у нормі, так і до розвитку патологій, 
асоційованих з ангіопатіями. Раніше було показа‑
но, що плазміноген регулює деякі функції тром‑
боцитів, однак його здатність модулювати їхні 
ангіогенні властивості досліджено недостатньо. 
Мета поданої роботи – визначити ефекти різних 
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форм плазміногену на утворе ння та секрецію 
тромбоцитами протеїнів – регуляторів ангіоге‑
незу. Відмиті тромбоцити людини одержували 
гель-фільтрацією на сефарозі-2В. Рівні експо‑
нованого Р-селектину (CD-62P) на плазматич‑
ній мембрані нестимульованих та активованих 
тромбоцитів вимірювали за допомогою протоко‑
вої цитофлуориметрії. Секрецію фактора росту 
ендотеліоцитів судин (VEGF) тромбоцитарного 
походження, а також фрагментацію плазміноге‑
ну та утворення ангіо статинів інтакт ними тром‑
боцитами та плазматичними мембранами тром‑
боцитів визначали за допомогою імуноблотингу. 
Показано, що за дії  тромбіну або колагену збіль‑
шувалась кількість Р-селектину на поверхні 
тромбоцитів, тоді як Lys-форма плазміногену 
пригнічувала агоністіндуковану тромбоцитар‑
ну секрецію. Lys-плазміноген, але не Glu-форма, 
інгібував агоніст індуковане вивільнення VEGF 
із тромбоцитів. Активація тромбоцитів сприяла 
істотному підсиленню розщеплення плазміноге‑
ну та утворенню ангіо статинів. Антитіла проти 
актину інгібували фрагментацію плазміноге‑
ну за інкубації із плазматичними мембранами 
тромбоцитів, що вказує на роль поверхнево-екс‑
понованого актину в перетворенні плазміногену 
на ангіостатини. Дослідження демонструє нову 
функцію плазміногену, яка полягає в обмеженні 
ангіогенної активності тромбоцитів через утво‑
рення ангіостатинів та інгібування секреції фак‑
тора росту ендотеліоцитів.
К л ю ч о в і  с л о в а: плазміноген, тромбо‑
цити, ангіогенез, фактор росту ендотеліоцитів 
судин (VEGF), ангіостатини.
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